trending Market Intelligence /marketintelligence/en/news-insights/trending/nxqaj_msqxbc34_wff78fq2 content esgSubNav
In This List

Aimmune Therapeutics names CEO

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aimmune Therapeutics names CEO

Aimmune Therapeutics Inc. appointed Jayson Dallas as director, president and CEO, effective June 19.

Dallas will replace Stephen Dilly, who disclosed plans to retire from the company in late 2017. Dilly will serve as a special adviser to the company till the end of 2018.

Most recently, Dallas served as the chief commercial officer of Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of products for rare and ultra-rare diseases.

Brisbane, Calif.-based Aimmune Therapeutics is a clinical-stage biopharmaceutical company, which develops and commercializes product candidates to treat peanut and other food allergies.